Anti-tubercular treatment regime for Musculoskeletal Tuberculosis.
Pokharel
R K
RK
Tribhuvan University Institute of Medicine, Maharajgunj, Kathmandu, Nepal. rohit@healthnet.org.np
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023801:Directly Observed Therapy; D004977:Ethambutol / Q000008:administration & dosage; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage; D009140:Musculoskeletal Diseases / Q000188:drug therapy*; D011718:Pyrazinamide / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage; D016896:Treatment Outcome; D014394:Tuberculosis, Osteoarticular / Q000188:drug therapy*
D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid; D012293:Rifampin